Intuitive Surgical, Inc. $ISRG Position Lessened by Elevatus Welath Management

Elevatus Welath Management lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 91.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 705 shares of the medical equipment provider’s stock after selling 7,487 shares during the quarter. Elevatus Welath Management’s holdings in Intuitive Surgical were worth $315,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ISRG. Tobam lifted its stake in Intuitive Surgical by 666.7% in the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 40 shares during the last quarter. Kilter Group LLC acquired a new position in shares of Intuitive Surgical during the second quarter valued at $27,000. Greykasell Wealth Strategies Inc. bought a new position in shares of Intuitive Surgical during the third quarter worth about $27,000. Caitlin John LLC bought a new position in shares of Intuitive Surgical during the third quarter worth about $30,000. Finally, Guerra Advisors Inc acquired a new stake in shares of Intuitive Surgical in the 3rd quarter worth about $37,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG opened at $492.87 on Thursday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $603.88. The stock’s fifty day moving average is $516.79 and its 200-day moving average is $512.60. The company has a market capitalization of $175.03 billion, a PE ratio of 62.47, a P/E/G ratio of 3.75 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The business had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same quarter in the prior year, the firm posted $2.21 earnings per share. The company’s revenue was up 18.8% on a year-over-year basis. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of several recent research reports. Truist Financial lifted their price objective on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Raymond James Financial raised their price target on shares of Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Argus cut their price target on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Royal Bank Of Canada boosted their price objective on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Barclays set a $712.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $615.86.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 133 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total value of $65,829.68. Following the completion of the sale, the vice president directly owned 660 shares of the company’s stock, valued at approximately $326,673.60. This represents a 16.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $485.01, for a total transaction of $312,831.45. Following the transaction, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. This trade represents a 28.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 37,907 shares of company stock valued at $19,997,187 in the last ninety days. 0.70% of the stock is owned by insiders.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Citi upgraded ISRG to Buy and set a $590 price target, calling out resilient med‑tech fundamentals — a clear near‑term catalyst that likely pushed buying interest. Read More.
• Positive Sentiment: Analyst coverage and commentary emphasize product momentum (da Vinci 5, Ion and SP platforms) and procedure growth, supporting revenue and recurring‑revenue visibility into 2026. Read More.
• Positive Sentiment: Intuitive closed the acquisition of regional da Vinci and Ion distribution businesses, consolidating distribution and potentially improving margin/recurring revenue capture. Read More.
• Neutral Sentiment: Seeking Alpha reiterated the company’s strong moat and solid Q4 results but flagged valuation (P/E ~63 vs. historical ~53) and recommended a Hold — this tempers upside for value‑oriented investors. Read More.
• Neutral Sentiment: MarketWatch noted ISRG outperformed peers on a strong trading day, reflecting today’s buying interest but not adding new fundamental news. Read More.
• Neutral Sentiment: MarketBeat’s roundup reiterates broad analyst support and a consensus target near $616, underpinning a constructive longer‑term view but noting mixed ratings (Buy/Hold). Read More.
• Negative Sentiment: Insider selling: multiple recent sales by senior executives (SVP Mark Brosius and EVP Myriam Curet) have been disclosed; while common for compensation/liquidity reasons, clustered insider sales can weigh on sentiment. Read More.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.